For this reason, we combined Doxo with a clinically approved HIF-1α inhibitor, the PX-478, or with TMZ, which had already demonstrated to down-regulate the expression level of this transcription factor in GBM cell lines by CMA induction [11, 19]. Here, HIF1A is linked to glioblastoma.